



# Estrategias para proteger el injerto esteatósico en el trasplante hepático

Araní Casillas Ramírez

**ADVERTIMENT.** La consulta d'aquesta tesi queda condicionada a l'acceptació de les següents condicions d'ús: La difusió d'aquesta tesi per mitjà del servei TDX ([www.tdx.cat](http://www.tdx.cat)) ha estat autoritzada pels titulars dels drets de propietat intel·lectual únicament per a usos privats emmarcats en activitats d'investigació i docència. No s'autoritza la seva reproducció amb finalitats de lucre ni la seva difusió i posada a disposició des d'un lloc aliè al servei TDX. No s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant al resum de presentació de la tesi com als seus continguts. En la utilització o cita de parts de la tesi és obligat indicar el nom de la persona autora.

**ADVERTENCIA.** La consulta de esta tesis queda condicionada a la aceptación de las siguientes condiciones de uso: La difusión de esta tesis por medio del servicio TDR ([www.tdx.cat](http://www.tdx.cat)) ha sido autorizada por los titulares de los derechos de propiedad intelectual únicamente para usos privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción con finalidades de lucro ni su difusión y puesta a disposición desde un sitio ajeno al servicio TDR. No se autoriza la presentación de su contenido en una ventana o marco ajeno a TDR (framing). Esta reserva de derechos afecta tanto al resumen de presentación de la tesis como a sus contenidos. En la utilización o cita de partes de la tesis es obligado indicar el nombre de la persona autora.

**WARNING.** On having consulted this thesis you're accepting the following use conditions: Spreading this thesis by the TDX ([www.tdx.cat](http://www.tdx.cat)) service has been authorized by the titular of the intellectual property rights only for private uses placed in investigation and teaching activities. Reproduction with lucrative aims is not authorized neither its spreading and availability from a site foreign to the TDX service. Introducing its content in a window or frame foreign to the TDX service is not authorized (framing). This rights affect to the presentation summary of the thesis as well as to its contents. In the using or citation of parts of the thesis it's obliged to indicate the name of the author.



# **Estrategias para proteger el injerto esteatósico en el trasplante hepático**

Tesis Doctoral presentada por

Araní Casillas Ramírez

para optar al título de

DOCTORA EN BIOMEDICINA POR LA UNIVERSIDAD DE BARCELONA

Director de Tesis:

Dra. Carmen Peralta Uroz

Tutor:

Dr. Ramon Bartrons Bach

2011

## Bibliografía

---

1. Tratado de Histología, 12ª edición. DW Fawcett. Editorial McGraw-Hill Interamericana, Madrid, 1997.
2. Hepatology, a textbook of liver disease, 4<sup>th</sup> edition. Zakim and Boyer. Saunders Editorial, Philadelphia, 2003.
3. Diseases of the liver and biliary system, 11<sup>th</sup> edition. Sherlock and J. Dooley. Blackwell Publishing Editorial, Oxford, 2002.
4. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, Kneteman NM, Lake JR, Martin P, McDiarmid SV, Rakela J, Shiffman ML, So SK, Wiesner RH. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. *Liver Transpl Surg* 1997;3(6):628-637.
5. Devlin J, O'Grady J. Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology. *Gut* 1999;45 Suppl 6:VI1-VI22.
6. Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, Neuhaus P, Lerut J, Salizzoni M, Pollard S, Muhlbacher F, Rogiers X, Garcia Valdecasas JC, Berenguer J, Jaeck D, Moreno Gonzalez E; European Liver Transplant Association. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. *Liver Transpl* 2003;9(12):1231-1243.
7. Haberal M, Dalgic A. New concepts in organ transplantation. *Transplant Proc* 2004;36(5):1219-1224.
8. Schulak JA. What's new in general surgery: transplantation. *J Am Coll Surg* 2005;200(3):409-417.
9. Fondevila C, Jiménez-Galanes S, García-Valdecasas JC. [How can the number of liver transplantations be increased?]. *Gastroenterol Hepatol* 2009;32(7):519-530.
10. Neuberger J. Developments in liver transplantation. *Gut* 2004;53(5):759-768.
11. Busuttil RW, Goss JA. Split liver transplantation. *Ann Surg* 1999;229(3):313-321.
12. Sauer IM, Pascher A, Steinmuller T, Settmacher U, Muller AR, Bechstein WO, Neuhaus P. Split liver and living donation liver transplantation: the Berlin experience. *Transplant Proc* 2001;33(1-2):1459-1460.
13. Bismuth H, Houssin D. Reduced-sized orthotopic liver graft in hepatic transplantation in children. *Surgery* 1984;95(3):367-370.
14. Inomata Y, Nakamura T, Uemoto S, Tanaka K, Wakabayashi G, Shimazu M. Domino split-liver transplantation from a living donor: case reports of in situ and ex situ splitting. *Liver Transpl* 2001;7(2):150-153.
15. Azoulay D, Samuel D, Castaing D, Adam R, Adams D, Said G, Bismuth H. Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy. *J Am Coll Surg* 1999;189(6):584-593.
16. Schmidt HH, Nashan B, Propsting MJ, Nakazato M, Flemming P, Kubicka S, Boker K, Pichlmayr R, Manns MP. Familial Amyloidotic Polyneuropathy: domino liver transplantation. *J Hepatol* 1999;30(2):293-298.
17. Monteiro E, Perdigoto R, Furtado AL. Liver transplantation for familial amyloid polyneuropathy. *Hepatogastroenterology* 1998;45(23):1375-1380.
18. Raia S, Nery JR, Mies S. Liver transplantation from live donors. *Lancet* 1989;2(8661):497.

19. Yamaoka Y, Washida M, Honda K, Tanaka K, Mori K, Shimahara Y, Okamoto S, Ueda M, Hayashi M, Tanaka A, et al. Liver transplantation using a right lobe graft from a living related donor. *Transplantation* 1994;57(7):1127-1130.
20. Marcos A, Fisher RA, Ham JM, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Posner MP. Right lobe living donor liver transplantation. *Transplantation* 1999;68(6):798-803.
21. Otte JB, de Ville de Goyet J, Reding R, Van Obbergh L, Veyckemans F, Carlier MA, De Kock M, Clement de Clety S, Clapuyt P, Sokal E, Lerut J, Delbeke I, Dierick V, Janssen M, Rosati R, Libert F. Pediatric liver transplantation: from the full-size liver graft to reduced, split, and living related liver transplantation. *Pediatr Surg Int* 1998;13(5-6):308-318.
22. Tanaka K, Uemoto S, Tokunaga Y, Fujita S, Sano K, Nishizawa T, Sawada H, Shirahase I, Kim HJ, Yamaoka Y, et al. Surgical techniques and innovations in living related liver transplantation. *Ann Surg* 1993;217(1):82-91.
23. Ozawa K, Uemoto S, Tanaka K, Kumada K, Yamaoka Y, Kobayashi N, Inamoto T, Shimahara Y, Mori K, Honda K, et al. An appraisal of pediatric liver transplantation from living relatives. Initial clinical experiences in 20 pediatric liver transplantations from living relatives as donors. *Ann Surg* 1992;216(5):547-553.
24. García-Valdecasas JC, Fuster J, Fondevila C, Calatayud D. [Adult living-donor liver transplantation]. *Gastroenterol Hepatol* 2009;32(8):577-583.
25. Grande L, Matus D, Manyalic M, Cabrer C, Rodriguez-Montalvo C, Rimola A, Navasa M, Garcia-Valdecasas JC, Visa J. Effect of donor age on graft outcome after liver transplantation. *Transplant Proc* 1999;31(6):2482-2483.
26. Jiménez Romero C, Moreno González E, Colina Ruíz F, Palma Carazo F, Loinaz Seguroloa C, Rodríguez González F, González Pinto I, García García I, Rodríguez Romano D, Moreno Sanz C. Use of octogenarian livers safely expands the donor pool. *Transplantation* 1999;68(4):572-575.
27. Keswani RN, Ahmed A, Keeffe EB. Older age and liver transplantation: a review. *Liver Transpl* 2004;10(8):957-967.
28. Melendez HV, Heaton ND. Understanding "marginal" liver grafts. *Transplantation* 1999;68(4):469-471.
29. Loinaz C, González EM. Marginal donors in liver transplantation. *Hepatogastroenterology* 2000;47(31):256-263.
30. Casillas-Ramírez A, Mosbah IB, Ramalho F, Roselló-Catafau J, Peralta C. Past and future approaches to ischemia-reperfusion lesion associated with liver transplantation. *Life Sci* 2006;79(20):1881-1194.
31. D'Alessandro AM, Hoffmann RM, Knechtle SJ, Eckhoff DE, Love RB, Kalayoglu M, Sollinger HW, Belzer FO. Successful extrarenal transplantation from non-heart-beating donors. *Transplantation* 1995;59(7):977-982.
32. Casavilla A, Ramirez C, Shapiro R, Nghiem D, Miracle K, Bronsther O, Randhawa P, Broznick B, Fung JJ, Starzl T. Experience with liver and kidney allografts from non-heart-beating donors. *Transplantation* 1995;59(2):197-203.
33. D'alessandro AM, Hoffmann RM, Knechtle SJ, Odorico JS, Becker YT, Musat A, Pirsch JD, Sollinger HW, Kalayoglu M. Liver transplantation from controlled non-heart-beating donors. *Surgery* 2000;128(4):579-588.
34. Shiroki R, Hoshinaga K, Horiba M, Izumitani M, Tsukiashi Y, Yanaoka M, Naide Y, Kanno T. Favorable prognosis of kidney allografts from unconditioned cadaveric donors whose procurement was initiated after cardiac arrest. *Transplant Proc* 1997;29(1-2):1388-1389.
35. Cho YW, Terasaki PI, Cecka JM. High kidney graft survival rates using non-heart-beating trauma donors. *Transplant Proc* 1998;30(7):3795-3796.
36. Hattori R, Ohshima S, Ono Y, Fujita T, Kinukawa T, Matsuura O. Long-term outcome of kidney transplants from non-heart-beating donors: multivariate analysis of factors affecting graft survival. *Transplant Proc* 1999;31(7):2847-2850.
37. Light JA, Barhyte DY, Gage FA, Sasaki TM, Aquino AO. Long-term graft survival after transplantation with kidneys from uncontrolled nonheartbeating donors. *Transplantation* 1999;68(12):1910-1911.

38. Abt P, Crawford M, Desai N, Markmann J, Olthoff K, Shaked A. Liver transplantation from controlled non-heart-beating donors: an increased incidence of biliary complications. *Transplantation* 2003;75(10):1659-1663.
39. Cooper JT, Chin LT, Krieger NR, Fernandez LA, Foley DP, Becker YT, Odorico JS, Knechtle SJ, Kalayoglu M, Sollinger HW, D'Alessandro AM. Donation after cardiac death: the university of wisconsin experience with renal transplantation. *Am J Transplant* 2004;4(9):1490-1494.
40. Manzarbeitia CY, Ortiz JA, Jeon H, Rothstein KD, Martinez O, Araya VR, Munoz SJ, Reich DJ. Long-term outcome of controlled, non-heart-beating donor liver transplantation. *Transplantation* 2004;78(2):211-215.
41. Reddy S, Zilvetti M, Brockmann J, McLaren A, Friend P. Liver transplantation from non-heart-beating donors: current status and future prospects. *Liver Transpl* 2004;10(10):1223-1232.
42. Koneru B, Tzakis AG, Bowman J 3rd, Cassavilla A, Zajko AB, Starzl TE. Postoperative surgical complications. *Gastroenterol Clin North Am* 1988 Mar;17(1):71-91.
43. Friend PJ, Lim S, Smith M, Jamieson NV, Rolles K, O'Grady J, Williams R, Calne RY. Liver transplantation in the Cambridge/King's College Hospital series—the first 400 patients. *Transplant Proc* 1989;21(1 Pt 2):2397-2398.
44. Clavien PA, Harvey PR, Strasberg SM. Preservation and reperfusion injuries in liver allografts. An overview and synthesis of current studies. *Transplantation* 1992 May;53(5):957-978.
45. Jaeschke H. Preservation injury: mechanisms, prevention and consequences. *J Hepatol* 1996;25(5):774-780.
46. Teoh NC, Farrell GC. Hepatic ischemia reperfusion injury: pathogenic mechanisms and basis for hepatoprotection. *J Gastroenterol Hepatol* 2003;18(8):891-902.
47. Selzner N, Rudiger H, Graf R, Clavien PA. Protective strategies against ischemic injury of the liver. *Gastroenterology* 2003;125(3):917-936.
48. Mor E, Klintmalm GB, Gonwa TA, Solomon H, Holman MJ, Gibbs JF, Watemberg I, Goldstein RM, Husberg BS. The use of marginal donors for liver transplantation. A retrospective study of 365 liver donors. *Transplantation* 1992;53(2):383-386.
49. Figueras J, Busquets J, Grande L, Jaurrieta E, Perez-Ferreiroa J, Mir J, Margarit C, Lopez P, Vazquez J, Casanova D, Bernardos A, De-Vicente E, Parrilla P, Ramon JM, Bou R. The deleterious effect of donor high plasma sodium and extended preservation in liver transplantation. A multivariate analysis. *Transplantation* 1996;61(3):410-413.
50. Koneru B, Tzakis AG, Bowman J 3rd, Cassavilla A, Zajko AB, Starzl TE. Postoperative surgical complications. *Gastroenterol Clin North Am* 1988;17(1):71-91.
51. Paulsen AW, Brajtford D, Klintmalm GB, Ramsay MA, Valek TR, Swygert TH. Intraoperative measurements related to subsequent hepatic graft failure. *Transplant Proc*. 1989 Feb;21(1 Pt 2):2337-8.
52. Mimeault R, Grant D, Ghent C, Duff J, Wall W. Analysis of donor and recipient variables and early graft function after orthotopic liver transplantation. *Transplant Proc* 1989;21(2):3355.
53. Neidecker J, Faure JL, Champetier P, Takvorian P, Landraud R, Delafosse B. Does end-tidal CO<sub>2</sub> pressure (PETCO<sub>2</sub>) reflect hepatic metabolism during orthotopic liver transplantation (OLT<sub>X</sub>)? *Transplant Proc* 1989;21(1 Pt 2):2339-2340.
54. Ohkohchi N, Sakurada M, Endoh T, Koyamada M, Katoh H, Koizumi M, Orii T, Satomi S, Taguchi Y, Mori S. Role of free radicals and energy synthesis on primary graft nonfunction in liver transplantation. *Transplant Proc* 1991;23(5):2416-2419.
55. Busuttil RW, Farmer DG, Yersiz H, Hiatt JR, McDiarmid SV, Goldstein LI, Saab S, Han S, Durazo F, Weaver M, Cao C, Chen T, Lipshutz GS, Holt C, Gordon S, Gornbein J, Amersi F, Ghobrial RM. Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. *Ann Surg*. 2005 Jun;241(6):905-918.

56. Vrochides D, Hassanain M, Barkun J, Tchervenkov J, Paraskevas S, Chaudhury P, Cantarovich M, Deschenes M, Wong P, Ghali P, Chan G, Metrakos P. Association of preoperative parameters with postoperative mortality and long-term survival after liver transplantation. *Can J Surg* 2011;54(2):101-106.
57. Goto M, Takei Y, Kawano S, Tsuji S, Fukui H, Fushimi H, Nishimura Y, Kashiwagi T, Fusamoto H, Kamada T. Tumor necrosis factor and endotoxin in the pathogenesis of liver and pulmonary injuries after orthotopic liver transplantation in the rat. *Hepatology* 1992;16(2):487-493.
58. Yost CS, Matthay MA, Gropper MA. Etiology of acute pulmonary edema during liver transplantation: a series of cases with analysis of the edema fluid. *Chest* 2001;119(1):219-223.
59. Casillas-Ramírez A, Mosbah IB, Franco-Gou R, Rimola A, Roselló-Catafau J, Peralta C. [Ischemia-reperfusion syndrome associated with liver transplantation: an update]. *Gastroenterol Hepatol* 2006;29(5):306-313.
60. Cursio R, Filippa N, Miele C, Van Obberghen E, Gugenheim J. Involvement of protein kinase B and mitogen-activated protein kinases in experimental normothermic liver ischaemia-reperfusion injury. *Br J Surg* 2006;93(6):752-761.
61. Massip-Salcedo M, Casillas-Ramirez A, Franco-Gou R, Bartrons R, Ben Mosbah I, Serafin A, Roselló-Catafau J, Peralta C. Heat shock proteins and mitogen-activated protein kinases in steatotic livers undergoing ischemia-reperfusion: some answers. *Am J Pathol* 2006;168(5):1474-1485.
62. Massip-Salcedo M, Zaouali MA, Padriisa-Altés S, Casillas-Ramirez A, Rodés J, Roselló-Catafau J, Peralta C. Activation of peroxisome proliferator-activated receptor-alpha inhibits the injurious effects of adiponectin in rat steatotic liver undergoing ischemia-reperfusion. *Hepatology* 2008;47(2):461-472.
63. Yoshinari D, Takeyoshi I, Kobayashi M, Koyama T, Iijima K, Ohwada S, Matsumoto K, Morishita Y. Effects of a p38 mitogen-activated protein kinase inhibitor as an additive to university of wisconsin solution on reperfusion injury in liver transplantation. *Transplantation* 2001;72(1):22-27.
64. Liang T, Xu S, Yu J, Shen K, Li D, Zheng S. Activation pattern of mitogen-activated protein kinases in early phase of different size liver isografts in rats. *Liver Transpl* 2005;11(12):1527-1532.
65. Kobayashi M, Takeyoshi I, Yoshinari D, Matsumoto K, Morishita Y. P38 mitogen-activated protein kinase inhibition attenuates ischemia-reperfusion injury of the rat liver. *Surgery* 2002;131(3):344-349.
66. King LA, Toledo AH, Rivera-Chavez FA, Toledo-Pereyra LH. Role of p38 and JNK in liver ischemia and reperfusion. *J Hepatobiliary Pancreat Surg* 2009;16(6):763-770.
67. Amersi F, Shen XD, Anselmo D, Melinek J, Iyer S, Southard DJ, Katori M, Volk HD, Busuttil RW, Buelow R, Kupiec-Weglinski JW. Ex vivo exposure to carbon monoxide prevents hepatic ischemia/reperfusion injury through p38 MAP kinase pathway. *Hepatology* 2002;35(4):815-823.
68. Kierner AK, Kulhanek-Heinze S, Gerwig T, Gerbes AL, Vollmar AM. Stimulation of p38 MAPK by hormonal preconditioning with atrial natriuretic peptide. *World J Gastroenterol* 2002;8(4):707-711.
69. Kobayashi K, Oshima K, Muraoka M, Akao T, Totsuka O, Shimizu H, Sato H, Tanaka K, Konno K, Matsumoto K, Takeyoshi I. Effect of atrial natriuretic peptide on ischemia-reperfusion injury in a porcine total hepatic vascular exclusion model. *World J Gastroenterol* 2007;13(25):3487-3492.
70. Gao Y, Wang Y, Pan MX, Sun EW, Shan YQ. [Protecting effects of p44/42 MAPK signal transduction pathway on hepatocytes in ischemic preconditioning]. *Zhonghua Gan Zang Bing Za Zhi* 2003;11(3):166-169.
71. Man K, Ng KT, Lee TK, Lo CM, Sun CK, Li XL, Zhao Y, Ho JW, Fan ST. FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers. *Am J Transplant* 2005;5(1):40-49.
72. Kaizu T, Ikeda A, Nakao A, Tsung A, Toyokawa H, Ueki S, Geller DA, Murase N. Protection of transplant-induced hepatic ischemia/reperfusion injury with carbon monoxide via MEK/ERK1/2 pathway downregulation. *Am J Physiol Gastrointest Liver Physiol* 2008;294(1):G236-G244.
73. Veteläinen R, van Vliet A, Gouma DJ, van Gulik TM. Steatosis as a risk factor in liver surgery. *Ann Surg* 2007;245(1):20-30.

74. McCormack L, Dutkowski P, El-Badry AM, Clavien PA. Liver transplantation using fatty livers: always feasible? *J Hepatol* 2011;54(5):1055-1062.
75. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. *Semin Liver Dis* 2001;21(1):105-113.
76. Ricci C, Longo R, Gioulis E, Bosco M, Pollesello P, Masutti F, Croce LS, Paoletti S, de Bernard B, Tiribelli C, Dalla Palma L. Noninvasive in vivo quantitative assessment of fat content in human liver. *J Hepatol* 1997;27(1):108-113.
77. Hayashi M, Tokunaga Y, Fujita T, Tanaka K, Yamaoka Y, Ozawa K. The effects of cold preservation on steatotic graft viability in rat liver transplantation. *Transplantation* 1993;56(2):282-287.
78. Seifalian AM, Chidambaram V, Rolles K, Davidson BR. In vivo demonstration of impaired microcirculation in steatotic human liver grafts. *Liver Transpl Surg* 1998;4(1):71-77.
79. Teramoto K, Bowers JL, Kruskal JB, Clouse ME. Hepatic microcirculatory changes after reperfusion in fatty and normal liver transplantation in the rat. *Transplantation* 1993;56(5):1076-1082.
80. Hakamada K, Sasaki M, Takahashi K, Umehara Y, Konn M. Sinusoidal flow block after warm ischemia in rats with diet-induced fatty liver. *J Surg Res* 1997;70(1):12-20.
81. Teramoto K, Bowers JL, Kruskal JB, Hara J, Iwai T, Endo M, Clouse ME. In vivo microscopic observation of fatty liver grafts after reperfusion. *Transplant Proc* 1994;26(4):2391.
82. Wada K, Fujimoto K, Fujikawa Y, Shibayama Y, Mitsui H, Nakata K. Sinusoidal stenosis as the cause of portal hypertension in choline deficient diet induced fatty cirrhosis of the rat liver. *Acta Pathol Jpn* 1974;24(2):207-217.
83. Serafín A, Roselló-Catafau J, Prats N, Xaus C, Gelpi E, Peralta C. Ischemic preconditioning increases the tolerance of Fatty liver to hepatic ischemia-reperfusion injury in the rat. *Am J Pathol* 2002;161(2):587-601.
84. Selzner M, Rüdiger HA, Sindram D, Madden J, Clavien PA. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. *Hepatology* 2000;32(6):1280-1288.
85. Koneru B, Dikdan G. Hepatic steatosis and liver transplantation current clinical and experimental perspectives. *Transplantation* 2002;73(3):325-330.
86. Koneru B, Fisher A, He Y, Klein KM, Skurnick J, Wilson DJ, de la Torre AN, Merchant A, Arora R, Samanta AK. Ischemic preconditioning in deceased donor liver transplantation: a prospective randomized clinical trial of safety and efficacy. *Liver Transpl* 2005;11(2):196-202.
87. Soltys K, Dikdan G, Koneru B. Oxidative stress in fatty livers of obese Zucker rats: rapid amelioration and improved tolerance to warm ischemia with tocopherol. *Hepatology* 2001;34(1):13-18.
88. Nardo B, Caraceni P, Pasini P, Domenicali M, Catena F, Cavallari G, Santoni B, Maiolini E, Grattagliano I, Vendemiale G, Trevisani F, Roda A, Bernardi M, Cavallari A. Increased generation of reactive oxygen species in isolated rat fatty liver during postischemic reoxygenation. *Transplantation* 2001;71(12):1816-1820.
89. Caraceni P, Domenicali M, Vendemiale G, Grattagliano I, Pertosa A, Nardo B, Morselli-Labate AM, Trevisani F, Palasciano G, Altomare E, Bernardi M. The reduced tolerance of rat fatty liver to ischemia reperfusion is associated with mitochondrial oxidative injury. *J Surg Res* 2005;124(2):160-168.
90. Jassem W, Fuggle SV, Rela M, Koo DD, Heaton ND. The role of mitochondria in ischemia/reperfusion injury. *Transplantation* 2002;73(4):493-499.
91. Leducq N, Delmas-Beauvieux MC, Bourdel-Marchasson I, Dufour S, Gallis JL, Canioni P, Diolez P. Mitochondrial and energetic dysfunctions of the liver during normothermic reperfusion: protective effect of cyclosporine and role of the mitochondrial permeability transition pore. *Transplant Proc* 2000;32(2):479-480.
92. Letteron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. *J Hepatol* 1996;24(2):200-208.
93. Reddy MC, Koneru B, Soni S, Patel D. 31P nuclear magnetic resonance study of phospholipids in ischemia/reperfusion injury in a rat fatty liver model. *Transplantation* 1996;61(8):1151-1155.

94. Day CP, James OF. Steatohepatitis: a tale of two "hits"? *Gastroenterology* 1998;114(4):842-845.
95. Curzio M, Esterbauer H, Dianzani MU. Chemotactic activity of hydroxyalkenals on rat neutrophils. *Int J Tissue React* 1985;7(2):137-142.
96. Fukumori T, Ohkohchi N, Tsukamoto S, Satomi S. Why is fatty liver unsuitable for transplantation? Deterioration of mitochondrial ATP synthesis and sinusoidal structure during cold preservation of a liver with steatosis. *Transplant Proc* 1997;29(1-2):412-415.
97. Selzner N, Selzner M, Jochum W, Clavien PA. Ischemic preconditioning protects the steatotic mouse liver against reperfusion injury: an ATP dependent mechanism. *J Hepatology* 2003;39(1):55-61.
98. Trevisani F, Colantoni A, Caraceni P and Van Thiel DH. The use of donor fatty liver for transplantation: a challenge or a quagmire? *J Hepatol* 1996;24(1):114-121.
99. Hui AM, Kawasaki S, Makuuchi M, Nakayama J, Ikegami T, Miyagawa S. Liver injury following normothermic ischemia in steatotic rat liver. *Hepatology* 1994;20(5):1287-1293.
100. Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. *J Hepatol* 1997;26 (Suppl 1):13-22.
101. Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis. *J Hepatol* 1997;26:43-53.
102. Miki C, Iriyama K, Mirza DF, Mayer AD, Buckels JA, Suzuki H, McMaster P. Postperfusion energy metabolism of steatotic graft and its relation to early graft viability following liver transplantation. *Dig Dis Sci* 1998;43(1):74-79.
103. Chavin KD, Yang S, Lin HZ, Chatham J, Chacko VP, Hoek JB, Walajtys-Rode E, Rashid A, Chen CH, Huang CC, Wu TC, Lane MD, Diehl AM. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. *J BiolChem* 1999;274(9):5692-5700.
104. Cortez-Pinto H, Zhi Lin H, Qi Yang S, Odwin Da Costa S, Diehl AM. Lipids up-regulate uncoupling protein 2 expression in rat hepatocytes. *Gastroenterology* 1999;116(5):1184-1193.
105. Rashid A, Wu TC, Huang CC, Chen CH, Lin HZ, Yang SQ, Lee FY, Diehl AM. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. *Hepatology* 1999;29(4):1131-1138.
106. Caraceni P, Bianchi C, Domenicali M, Maria Pertosa A, Maiolini E, Parenti Castelli G, Nardo B, Trevisani F, Lenaz G, Bernardi M. Impairment of mitochondrial oxidative phosphorylation in rat fatty liver exposed to preservation-reperfusion injury. *J Hepatol* 2004;41(1):82-88.
107. Nardo B, Grattagliano I, Domenicali M, Caraceni P, Catena F, Santoni B, Turi P, Cavallari G, Dall'Agata M, Trevisani F, Bernardi M, Cavallari A. Mitochondrial oxidative injury in rat fatty livers exposed to warm ischemia-reperfusion. *Transplant Proc* 2000;32(1):51.
108. Vendemiale G, Grattagliano I, Caraceni P, Caraccio G, Domenicali M, Dall'Agata M, Trevisani F, Guerrieri F, Bernardi M, Altomare E. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: effect of the nutritional status. *Hepatology* 2001;33(4):808-815.
109. Fukumori T, Ohkohchi N, Tsukamoto S, Satomi S. The mechanism of injury in a steatotic liver graft during cold preservation. *Transplantation* 1999;67(2):195-200.
110. Nakano H, Nagasaki H, Barama A, Boudjema K, Jaeck D, Kumada K, Tatsuno M, Baek Y, Kitamura N, Suzuki T, Yamaguchi M. The effects of N-acetylcysteine and anti-intercellular adhesion molecule-1 monoclonal antibody against ischemia-reperfusion injury of the rat steatotic liver produced by a choline-methionine-deficient diet. *Hepatology* 1997;26(3):670-678.
111. Stachlewitz RF, Gao W, Zhong Z, Connor HD, Mason RP, Thurman RG. Generation of lipid free radicals by adherent leukocytes from transplanted rat liver. *Transpl Int* 1998;11(5):353-360.
112. Yamada S, Iida T, Tabata T, Nomoto M, Kishikawa H, Kohno K, Eto S. Alcoholic fatty liver differentially induces a neutrophil-chemokine and hepatic necrosis after ischemia-reperfusion in rat. *Hepatology* 2000;32(2):278-288.



113. Koneru B, Reddy MC, dela Torre AN, Patel D, Ippolito T, Ferrante RJ. Studies of hepatic warm ischemia in the obese Zucker rat. *Transplantation* 1995;59(7):942-946.
114. Sun CK, Zhang XY, Zimmermann A, Davis G, Wheatley AM. Effect of ischemia-reperfusion injury on the microcirculation of the steatotic liver of the Zucker rat. *Transplantation* 2001;72(10):1625-1631.
115. Amersi F, Farmer DG, Shaw GD, Kato H, Coito AJ, Kaldas F, Zhao D, Lassman CR, Melinek J, Ma J, Volk HD, Kupiec-Weglinski JW, Busuttil RW. P-selectin glycoprotein ligand-1 (rPSGL-Ig)-mediated blockade of CD62 selectin molecules protects rat steatotic liver grafts from ischemia/reperfusion injury. *Am J Transplant* 2002;2(7):600-608.
116. Amersi F, Shen XD, Moore C, Melinek J, Busuttil RW, Kupiec-Weglinski JW, Coito AJ. Fibronectin-alpha 4 beta 1 integrin-mediated blockade protects genetically fat Zucker rat livers from ischemia/reperfusion injury. *Am J Pathol* 2003;162(4):1229-1239.
117. Fondevila C, Shen XD, Moore C, Busuttil RW, Coito AJ. Cyclic RGD peptides with high affinity for alpha5beta1 integrin protect genetically fat Zucker rat livers from cold ischemia/reperfusion injury. *Transplant Proc* 2005;37(4):1679-1681.
118. Zhong Z, Connor H, Mason RP, Qu W, Stachlewitz RF, Gao W, Lemasters JJ, Thurman RG. Destruction of Kupffer cells increases survival and reduces graft injury after transplantation of fatty livers from ethanol-treated rats. *Liver Transpl Surg* 1996;2(5):383-387.
119. Jaeschke H, Lemasters JJ. Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. *Gastroenterology* 2003;125(4):1246-1257.
120. Hong F, Radaeva S, Pan HN, Tian Z, Veech R, Gao B. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. *Hepatology* 2004;40(4):933-941.
121. Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. *J Gastrointest Surg* 1998;2(3):292-298.
122. Crowley H, Lewis WD, Gordon F, Jenkins R, Khettry U. Steatosis in donor and transplant liver biopsies. *Hum Pathol* 2000;31(10):1209-1213.
123. de Rougemont O, Lehmann K, Clavien PA. Preconditioning, organ preservation, and postconditioning to prevent ischemia-reperfusion injury to the liver. *Liver Transpl* 2009;15(10):1172-1182.
124. Ben Mosbah I, Roselló-Catafau J, Franco-Gou R, Abdennebi HB, Saidane D, Ramella-Virieux S, Boillot O, Peralta C. Preservation of steatotic livers in IGL-1 solution. *Liver Transpl* 2006;12(8):1215-1223.
125. Ichim TE, Li M, Qian H, Popov IA, Rycerz K, Zheng X, White D, Zhong R, Min WP. RNA interference: a potent tool for gene-specific therapeutics. *Am J Transplant* 2004;4(8):1227-1236.
126. Llacuna L, Marí M, Garcia-Ruiz C, Fernandez-Checa JC, Morales A. Critical role of acidic sphingomyelinase in murine hepatic ischemia-reperfusion injury. *Hepatology* 2006;44(3):561-572.
127. Sass G, Shembade ND, Haimerl F, Lamoureux N, Hashemolhosseini S, Tannapfel A, Tiegs G. TNF pretreatment interferes with mitochondrial apoptosis in the mouse liver by A20-mediated down-regulation of Bax. *J Immunol* 2007;179(10):7042-7049.
128. Li X, Zhang JF, Lu MQ, Yang Y, Xu C, Li H, Wang GS, Cai CJ, Chen GH. Alleviation of ischemia-reperfusion injury in rat liver transplantation by induction of small interference RNA targeting Fas. *Langenbecks Arch Surg* 2007;392(3):345-351.
129. Contreras JL, Vilatoba M, Eckstein C, Bilbao G, Anthony Thompson J, Eckhoff DE. Caspase-8 and caspase-3 small interfering RNA decreases ischemia/reperfusion injury to the liver in mice. *Surgery* 2004;136(2):390-400.
130. Pellish RS, Nasir A, Ramratnam B, Moss SF. Review article: RNA interference--potential therapeutic applications for the gastroenterologist. *Aliment Pharmacol Ther* 2008;27(9):715-723.

131. Fernández L, Heredia N, Peralta C, Xaus C, Roselló-Catafau J, Rimola A, Marco A, Serafín A, Deulofeu R, Gelpí E, Grande L. Role of ischemic preconditioning and the portosystemic shunt in the prevention of liver and lung damage after rat liver transplantation. *Transplantation* 2003;76(2):282-289.
132. Rüdiger HA, Kang KJ, Sindram D, Riehle HM, Clavien PA. Comparison of ischemic preconditioning and intermittent and continuous inflow occlusion in the murine liver. *Ann Surg* 2002;235(3):400-407.
133. Peralta C, Prats N, Xaus C, Gelpí E, Roselló-Catafau J. Protective effect of liver ischemic preconditioning on liver and lung injury induced by hepatic ischemia-reperfusion in the rat. *Hepatology* 1999;30(6):1481-1489.
134. Belghiti J, Noun R, Malafosse R, Jagot P, Sauvanet A, Pierangeli F, Marty J, Farges O. Continuous versus intermittent portal triad clamping for liver resection: a controlled study. *Ann Surg* 1999;229(3):369-375.
135. Clavien PA, Yadav S, Sindram D, Bentley RC. Protective effects of ischemic preconditioning for liver resection performed under inflow occlusion in humans. *Ann Surg* 2000;232(2):155-162.
136. Clavien PA, Selzner M, Rüdiger HA, Graf R, Kadry Z, Rousson V, Jochum W. A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning. *Ann Surg* 2003;238(6):843-852.
137. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation* 1986;74(5):1124-1136.
138. Heurteaux C, Lauritzen I, Widmann C, Lazdunski M. Essential role of adenosine, adenosine A1 receptors, and ATP-sensitive K<sup>+</sup> channels in cerebral ischemic preconditioning. *Proc Natl Acad Sci U S A* 1995;92(10):4666-4670.
139. Peralta C, Hotter G, Closa D, Prats N, Xaus C, Gelpí E, Rosello-Catafau J. The protective role of adenosine in inducing nitric oxide synthesis in rat liver ischemia preconditioning is mediated by activation of adenosine A2 receptors. *Hepatology* 1999;29(1):126-132.
140. Hoshida S, Yamashita N, Otsu K, Hori M. Repeated physiologic stresses provide persistent cardioprotection against ischemia-reperfusion injury in rats. *J Am Coll Cardiol* 2002;40(4):826-831.
141. Peralta C, Hotter G, Closa D, Gelpí E, Bulbena O, Roselló-Catafau J. Protective effect of preconditioning on the injury associated to hepatic ischemia-reperfusion in the rat: role of nitric oxide and adenosine. *Hepatology* 1997;25(4):934-937.
142. Massip-Salcedo M, Roselló-Catafau J, Prieto J, Avila MA, Peralta C. The response of the hepatocyte to ischemia. *Liver Int* 2007;27(1):6-16.
143. Peralta C, Closa D, Xaus C, Gelpí E, Roselló-Catafau J, Hotter G. Hepatic preconditioning in rats is defined by a balance of adenosine and xanthine. *Hepatology* 1998;28(3):768-773.
144. Yin DP, Sankary HN, Chong AS, Ma LL, Shen J, Foster P, Williams JW. Protective effect of ischemic preconditioning on liver preservation-reperfusion injury in rats. *Transplantation* 1998;66(2):152-157.
145. Arai M, Thurman RG, Lemasters JJ. Contribution of adenosine A(2) receptors and cyclic adenosine monophosphate to protective ischemic preconditioning of sinusoidal endothelial cells against Storage/Reperfusion injury in rat livers. *Hepatology* 2000;32(2):297-302.
146. Peralta C, Closa D, Hotter G, Gelpí E, Prats N, Roselló-Catafau J. Liver ischemic preconditioning is mediated by the inhibitory action of nitric oxide on endothelin. *Biochem Biophys Res Commun* 1996;229(1):264-270.
147. Pabla R, Buda AJ, Flynn DM, Blessé SA, Shin AM, Curtis MJ, Lefer DJ. Nitric oxide attenuates neutrophil-mediated myocardial contractile dysfunction after ischemia and reperfusion. *Circ Res* 1996;78(1):65-72.
148. Naito Y, Yoshikawa T, Matsuyama K, Yagi N, Arai M, Nakamura Y, Kaneko T, Yoshida N, Kondo M. Neutrophils, lipid peroxidation, and nitric oxide in gastric reperfusion injury in rats. *Free Radic Biol Med* 1998;24(3):494-502.

149. Koepfel TA, Thies JC, Schemmer P, Trauner M, Gebhard MM, Otto G, Post S. Inhibition of nitric oxide synthesis in ischemia/reperfusion of the rat liver is followed by impairment of hepatic microvascular blood flow. *J Hepatol* 1997;27(1):163-169.
150. Gong JP, Tu B, Wang W, Peng Y, Li SB, Yan LN. Protective effect of nitric oxide induced by ischemic preconditioning on reperfusion injury of rat liver graft. *World J Gastroenterol* 2004;10(1):73-76.
151. Peralta C, Rull R, Rimola A, Deulofeu R, Roselló-Catafau J, Gelpí E, Rodés J. Endogenous nitric oxide and exogenous nitric oxide supplementation in hepatic ischemia-reperfusion injury in the rat. *Transplantation* 2001;71(4):529-536.
152. Wang Y, Lawson JA, Jaeschke H. Differential effect of 2-aminoethyl-isothiourea, an inhibitor of the inducible nitric oxide synthase, on microvascular blood flow and organ injury in models of hepatic ischemia-reperfusion and endotoxemia. *Shock* 1998;10(1):20-25.
153. Yagnik GP, Takahashi Y, Tsoulfas G, Reid K, Murase N, Geller DA. Blockade of the L-arginine/NO synthase pathway worsens hepatic apoptosis and liver transplant preservation injury. *Hepatology* 2002;36(3):573-581.
154. Rivera-Chavez FA, Toledo-Pereyra LH, Dean RE, Crouch L, Ward PA. Exogenous and endogenous nitric oxide but not iNOS inhibition improves function and survival of ischemically injured livers. *J Invest Surg* 2001;14(5):267-273.
155. Ohmori H, Dhar DK, Nakashima Y, Hashimoto M, Masumura S, Nagasue N. Beneficial effects of FK409, a novel nitric oxide donor, on reperfusion injury of rat liver. *Transplantation* 1998;66(5):579-585.
156. Längle F, Steininger R, Waldmann E, Grünberger T, Benditte H, Mittlböck M, Soliman T, Schindl M, Windberger U, Mühlbacher F, Roth E. Improvement of cardiac output and liver blood flow and reduction of pulmonary vascular resistance by intravenous infusion of L-arginine during the early reperfusion period in pig liver transplantation. *Transplantation* 1997;63(9):1225-1233.
157. Jones SM, Thurman RG. L-arginine minimizes reperfusion injury in a low-flow, reflow model of liver perfusion. *Hepatology* 1996;24(1):163-168.
158. Geller DA, Chia SH, Takahashi Y, Yagnik GP, Tsoulfas G, Murase N. Protective role of the L-arginine-nitric oxide synthase pathway on preservation injury after rat liver transplantation. *JPEN J Parenter Enteral Nutr* 2001;25(3):142-147.
159. Carrasco-Chaumel E, Roselló-Catafau J, Bartrons R, Franco-Gou R, Xaus C, Casillas A, Gelpí E, Rodés J, Peralta C. Adenosine monophosphate-activated protein kinase and nitric oxide in rat steatotic liver transplantation. *J Hepatol* 2005;43(6):997-1006.
160. Fernández L, Carrasco-Chaumel E, Serafín A, Xaus C, Grande L, Rimola A, Roselló-Catafau J, Peralta C. Is ischemic preconditioning a useful strategy in steatotic liver transplantation? *Am J Transplant* 2004;4(6):888-899.
161. Funaki H, Shimizu K, Harada S, Tsuyama H, Fushida S, Tani T, Miwa K. Essential role for nuclear factor kappaB in ischemic preconditioning for ischemia-reperfusion injury of the mouse liver. *Transplantation* 2002;74(4):551-556.
162. Ricciardi R, Shah SA, Wheeler SM, Quarfordt SH, Callery MP, Meyers WC, Chari RS. Regulation of NFkappaB in hepatic ischemic preconditioning. *J Am Coll Surg* 2002;195(3):319-326.
163. Teoh N, Dela Pena A, Farrell G. Hepatic ischemic preconditioning in mice is associated with activation of NF-kappaB, p38 kinase, and cell cycle entry. *Hepatology* 2002;36(1):94-102.
164. Peralta C, Bulbena O, Xaus C, Prats N, Cutrin JC, Poli G, Gelpi E, Roselló-Catafau J. Ischemic preconditioning: a defense mechanism against the reactive oxygen species generated after hepatic ischemia reperfusion. *Transplantation* 2002;73(8):1203-1211.
165. Sindram D, Rüdiger HA, Upadhyia AG, Strasberg SM, Clavien PA. Ischemic preconditioning protects against cold ischemic injury through an oxidative stress dependent mechanism. *J Hepatol* 2002;36(1):78-84.

166. Teoh N, Leclercq I, Pena AD, Farrell G. Low-dose TNF-alpha protects against hepatic ischemia-reperfusion injury in mice: implications for preconditioning. *Hepatology* 2003;37(1):118-128.
167. Serafín A, Fernández-Zabalegui L, Prats N, Wu ZY, Roselló-Catafau J, Peralta C. Ischemic preconditioning: tolerance to hepatic ischemia-reperfusion injury. *Histol Histopathol* 2004;19(1):281-289.
168. Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. *Am J Physiol Gastrointest Liver Physiol* 2003;284(1):G15-G26.
169. Iwasaki Y, Tagaya N, Hattori Y, Yamaguchi K, Kubota K. Protective effect of ischemic preconditioning against intermittent warm-ischemia-induced liver injury. *J Surg Res* 2002;107(1):82-92.
170. Ricciardi R, Schaffer BK, Kim RD, Shah SA, Donohue SE, Wheeler SM, Quarfordt SH, Callery MP, Meyers WC, Chari RS. Protective effects of ischemic preconditioning on the cold-preserved liver are tyrosine kinase dependent. *Transplantation* 2001;72(3):406-412.
171. Sawaya DE Jr, Brown M, Minardi A, Bilton B, Burney D, Granger DN, McDonald JC, Zibari GB. The role of ischemic preconditioning in the recruitment of rolling and adherent leukocytes in hepatic venules after ischemia/reperfusion. *J Surg Res* 1999;85(1):163-170.
172. Zapletal C, Maksan SM, Lehmann T, Guenther L, Fallsehr C, Mehrabi A, Weiss G, Golling M, Gebhard MM, Herfarth C, Klar E. Ischemic preconditioning improves liver microcirculation after ischemia/reperfusion. *Transplant Proc* 1999;31(8):3260-3262.
173. Shinoda M, Shimazu M, Wakabayashi G, Tanabe M, Hoshino K, Kitajima M. Tumor necrosis factor suppression and microcirculatory disturbance amelioration in ischemia/reperfusion injury of rat liver after ischemic preconditioning. *J Gastroenterol Hepatol* 2002;17(11):1211-1219.
174. Koti RS, Yang W, Glantzounis G, Quaglia A, Davidson BR, Seifalian AM. Effect of ischaemic preconditioning on hepatic oxygenation, microcirculation and function in a rat model of moderate hepatic steatosis. *Clin Sci (Lond)* 2005;108(1):55-63.
175. Howell JG, Zibari GB, Brown MF, Burney DL, Sawaya DE, Olinde JG, Granger DN, McDonald JC. Both ischemic and pharmacological preconditioning decrease hepatic leukocyte/endothelial cell interactions. *Transplantation* 2000;69(2):300-303.
176. Arai M, Thurman RG, Lemasters JJ. Ischemic preconditioning of rat livers against cold storage-reperfusion injury: role of nonparenchymal cells and the phenomenon of heterologous preconditioning. *Liver Transpl* 2001;7(4):292-299.
177. Cutrin JC, Perrelli MG, Cavalieri B, Peralta C, Roselló-Catafau J, Poli G. Microvascular dysfunction induced by reperfusion injury and protective effect of ischemic preconditioning. *Free Radic Biol Med* 2002;33(9):1200-1208.
178. Peralta C, Bulbena O, Xaus C, Prats N, Cutrin JC, Poli G, Gelpi E, Roselló-Catafau J. Ischemic preconditioning: a defense mechanism against the reactive oxygen species generated after hepatic ischemia reperfusion. *Transplantation* 2002;73(8):1203-1211.
179. Fernández L, Heredia N, Grande L, Gómez G, Rimola A, Marco A, Gelpí E, Roselló-Catafau J, Peralta C. Preconditioning protects liver and lung damage in rat liver transplantation: role of xanthine/xanthine oxidase. *Hepatology* 2002;36(3):562-572.
180. Yuan GJ, Ma JC, Gong ZJ, Sun XM, Zheng SH, Li X. Modulation of liver oxidant-antioxidant system by ischemic preconditioning during ischemia/reperfusion injury in rats. *World J Gastroenterol* 2005;11(12):1825-1828.
181. Peralta C, Perales JC, Bartrons R, Mitchell C, Gilgenkrantz H, Xaus C, Prats N, Fernández L, Gelpí E, Panés J, Roselló-Catafau J. The combination of ischemic preconditioning and liver Bcl-2 overexpression is a suitable strategy to prevent liver and lung damage after hepatic ischemia-reperfusion. *Am J Pathol* 2002;160(6):2111-2122.
182. Serafín A, Roselló-Catafau J, Prats N, Gelpí E, Rodés J, Peralta C. Ischemic preconditioning affects interleukin release in fatty livers of rats undergoing ischemia/reperfusion. *Hepatology* 2004;39(3):688-698.

183. Peralta C, Fernández L, Panés J, Prats N, Sans M, Piqué JM, Gelpí E, Roselló-Catafau J. Preconditioning protects against systemic disorders associated with hepatic ischemia-reperfusion through blockade of tumor necrosis factor-induced P-selectin up-regulation in the rat. *Hepatology* 2001;33(1):100-113.
184. Yadav SS, Sindram D, Perry DK, Clavien PA. Ischemic preconditioning protects the mouse liver by inhibition of apoptosis through a caspase-dependent pathway. *Hepatology* 1999;30(5):1223-1231.
185. Zhang SJ, Chen S. The role of ischemic preconditioning in rat liver graft. *Transplant Proc* 2004;36(7):1970-1972.
186. Cavalieri B, Perrelli MG, Aragno M, Mastrocola R, Corvetti G, Durazzo M, Poli G, Cutrì JC. Ischemic preconditioning attenuates the oxidant-dependent mechanisms of reperfusion cell damage and death in rat liver. *Liver Transpl* 2002;8(11):990-999.
187. Choukèr A, Schachtner T, Schauer R, Dugas M, Löhe F, Martignoni A, Pollwein B, Niklas M, Rau HG, Jauch KW, Peter K, Thiel M. Effects of Pringle manoeuvre and ischaemic preconditioning on haemodynamic stability in patients undergoing elective hepatectomy: a randomized trial. *Br J Anaesth* 2004;93(2):204-211.
188. Li SQ, Liang LJ, Huang JF, Li Z. Ischemic preconditioning protects liver from hepatectomy under hepatic inflow occlusion for hepatocellular carcinoma patients with cirrhosis. *World J Gastroenterol* 2004;10(17):2580-2584.
189. Nuzzo G, Giuliantè F, Vellone M, De Cosmo G, Ardito F, Murazio M, D'Acapito F, Giovannini I. Pedicle clamping with ischemic preconditioning in liver resection. *Liver Transpl* 2004;10(2 Suppl 1):S53-S57.
190. Azoulay D, Del Gaudio M, Andreani P, Ichai P, Sebag M, Adam R, Scatton O, Min BY, Delvard V, Lemoine A, Bismuth H, Castaing D. Effects of 10 minutes of ischemic preconditioning of the cadaveric liver on the graft's preservation and function: the ying and the yang. *Ann Surg* 2005;242(1):133-139.
191. Jassem W, Fuggle SV, Cerundolo L, Heaton ND, Rela M. Ischemic preconditioning of cadaver donor livers protects allografts following transplantation. *Transplantation* 2006;81(2):169-174.
192. Cescon M, Grazi GL, Grassi A, Ravaioli M, Vetrone G, Ercolani G, Varotti G, D'Errico A, Ballardini G, Pinna AD. Effect of ischemic preconditioning in whole liver transplantation from deceased donors. A pilot study. *Liver Transpl* 2006;12(4):628-635.
193. Amador A, Grande L, Martí J, Deulofeu R, Miquel R, Solá A, Rodríguez-Laiz G, Ferrer J, Fondevila C, Charco R, Fuster J, Hotter G, García-Valdecasas JC. Ischemic pre-conditioning in deceased donor liver transplantation: a prospective randomized clinical trial. *Am J Transplant* 2007;7(9):2180-2189.
194. Koneru B, Fisher A, He Y, Klein KM, Skurnick J, Wilson DJ, de la Torre AN, Merchant A, Arora R, Samanta AK. Ischemic preconditioning in deceased donor liver transplantation: a prospective randomized clinical trial of safety and efficacy. *Liver Transpl* 2005;11(2):196-202.
195. Koneru B, Shareef A, Dikdan G, Desai K, Klein KM, Peng B, Wachsberg RH, de la Torre AN, Debroy M, Fisher A, Wilson DJ, Samanta AK. The ischemic preconditioning paradox in deceased donor liver transplantation-evidence from a prospective randomized single blind clinical trial. *Am J Transplant* 2007;7(12):2788-2796.
196. Desai KK, Dikdan GS, Shareef A, Koneru B. Ischemic preconditioning of the liver: a few perspectives from the bench to bedside translation. *Liver Transpl* 2008;14(11):1569-1577.
197. Tacchini L, Cairo G, De Ponti C, Massip M, Roselló-Catafau J, Peralta C. Up regulation of IL-6 by ischemic preconditioning in normal and fatty rat livers: association with reduction of oxidative stress. *Free Radic Res* 2006;40(11):1206-1217.
198. Niemann CU, Hirose R, Liu T, Behrends M, Brown JL, Kominsky DF, Roberts JP, Serkova N. Ischemic preconditioning improves energy state and transplantation survival in obese Zucker rat livers. *Anesth Analg* 2005;101(6):1577-1583.
199. Franchello A, Gilbo N, David E, Ricchiuti A, Romagnoli R, Cerutti E, Salizzoni M. Ischemic preconditioning (IP) of the liver as a safe and protective technique against ischemia/reperfusion injury (IRI). *Am J Transplant* 2009;9(7):1629-1639.

200. Beck-Schimmer B, Breitenstein S, Urech S, De Conno E, Wittlinger M, Puhan M, Jochum W, Spahn DR, Graf R, Clavien PA. A randomized controlled trial on pharmacological preconditioning in liver surgery using a volatile anesthetic. *Ann Surg* 2008;248(6):909-918.
201. Kim YI, Hwang YJ, Song KE, Yun YK, Lee JW, Chun BY. Hepatocyte protection by a protease inhibitor against ischemia/reperfusion injury of human liver. *J Am Coll Surg* 2002;195(1):41-50.
202. Aldrighetti L, Pulitanò C, Arru M, Finazzi R, Catena M, Soldini L, Comotti L, Ferla G. Impact of preoperative steroids administration on ischemia-reperfusion injury and systemic responses in liver surgery: a prospective randomized study. *Liver Transpl* 2006;12(6):941-949.
203. Dünschede F, Erbes K, Kircher A, Westermann S, Seifert J, Schad A, Oliver K, Kiemer AK, Theodor J. Reduction of ischemia reperfusion injury after liver resection and hepatic inflow occlusion by alpha-lipoic acid in humans. *World J Gastroenterol* 2006;12(42):6812-6817.
204. Kotsch K, Ulrich F, Reutzel-Selke A, Pascher A, Faber W, Warnick P, Hoffman S, Francuski M, Kunert C, Kuecuk O, Schumacher G, Wesslau C, Lun A, Kohler S, Weiss S, Tullius SG, Neuhaus P, Pratschke J. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial. *Ann Surg* 2008;248(6):1042-1050.
205. Bogetti D, Sankary HN, Jarzembowski TM, Manzelli A, Knight PS, Thielke J, Chejfec G, Cotler S, Oberholzer J, Testa G, Benedetti E. Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury. *Clin Transplant* 2005;19(4):507-511.
206. Bader M, Peters J, Baltatu O, Müller DN, Luft FC, Ganten D. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. *J Mol Med (Berl)* 2001;79(2-3):76-102.
207. Leung PS. The peptide hormone angiotensin II: its new functions in tissues and organs. *Curr Protein Pept Sci* 2004;5(4):267-273.
208. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: From angiotensin I to angiotensin (1-7). *Cardiovasc Res* 2007;73(3):463-469.
209. Santos RA, Ferreira AJ. Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. *Cardiovasc Drug Rev* 2006;24(3-4):239-246.
210. Varagic J, Trask AJ, Jessup JA, Chappell MC, Ferrario CM. New angiotensins. *J Mol Med (Berl)* 2008;86(6):663-671.
211. Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). *Hypertension* 2003;42(4):574-579.
212. Reudelhuber TL. A place in our hearts for the lowly angiotensin 1-7 peptide? *Hypertension* 2006;47(5):811-815.
213. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). *Hypertension* 1997;30(3 Pt 2):535-541.
214. Pereira RM, Dos Santos RA, Teixeira MM, Leite VH, Costa LP, da Costa Dias FL, Barcelos LS, Collares GB, Simões e Silva AC. The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1-7). *J Hepatol* 2007;46(4):674-681.
215. Casillas-Ramirez A, Amine-Zaouali M, Massip-Salcedo M, Padriisa-Altés S, Bintanel-Morcillo M, Ramalho F, Serafín A, Rimola A, Arroyo V, Rodés J, Roselló-Catafau J, Peralta C. Inhibition of angiotensin II action protects rat steatotic livers against ischemia-reperfusion injury. *Crit Care Med* 2008;36(4):1256-1266.
216. Araya J, Tsuruma T, Hirata K, Yagihashi A, Watanabe N. TCV-116, an angiotensin II type 1 receptor antagonist, reduces hepatic ischemia-reperfusion injury in rats. *Transplantation* 2002;73(4):529-534.
217. Guo L, Richardson KS, Tucker LM, Doll MA, Hein DW, Arteel GE. Role of the renin-angiotensin system in hepatic ischemia reperfusion injury in rats. *Hepatology* 2004;40(3):583-589.

218. Takada G, Jin MB, Masuko H, Yamashita K, Kitagawa N, Takeda K, Sakurai N, Kon Y, Horiuchi H, Shimamura T, Furukawa H, Todo S. Role of local renin-angiotensin system in warm ischemia and reperfusion injury of the liver. *Transplant Proc* 2001;33(1-2):824-825.
219. Anthuber M, Farkas S, Rihl M, Menger MD, Schildberg FW, Jauch KW, Messmer K. Angiotensin-converting enzyme inhibition by enalapril: a novel approach to reduce ischemia/reperfusion damage after experimental liver transplantation. *Hepatology* 1997;25(3):648-651.
220. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. *Lancet* 1995;345(8951):669-685.
221. Rutherford JD, Pfeffer MA, Moyé LA, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Rouleau JL, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. *Circulation* 1994;90(4):1731-1738.
222. Jeserich M, Ihling C, Allgaier HP, Berg PA, Heilmann C. Acute liver failure due to enalapril. *Herz* 2000;25(7):689-693.
223. Romero-Gómez M, Miralles EJ, García Díaz E, Robles A, Suárez E, Castro M. Hepatotoxicity induced by fosinopril. *J Hepatol* 2001;35(2):309-310.
224. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snively DB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet* 1997;349(9054):747-752.
225. Xiao XH, Allen DG. The role of endogenous angiotensin II in ischaemia, reperfusion and preconditioning of the isolated rat heart. *Pflugers Arch* 2003;445(6):643-650.
226. Butler KL, Huang AH, Gwathmey JK. AT1-receptor blockade enhances ischemic preconditioning in hypertrophied rat myocardium. *Am J Physiol* 1999;277(6 Pt 2):H2482-H2487.
227. Sato M, Engelman RM, Otani H, Maulik N, Rousou JA, Flack JE 3rd, Deaton DW, Das DK. Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms. *Circulation* 2000;102(19 Suppl 3):III346-III351.
228. Jugdutt BI. Nitric oxide and cardiovascular protection. *Heart Fail Rev* 2003;8(1):29-34.
229. Bataller R, Sancho-Bru P, Ginès P, Lora JM, Al-Garawi A, Solé M, Colmenero J, Nicolás JM, Jiménez W, Weich N, Gutiérrez-Ramos JC, Arroyo V, Rodés J. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. *Gastroenterology* 2003;125(1):117-125.
230. Diaz RJ, Wilson GJ. Selective blockade of AT1 angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts. *J Mol Cell Cardiol* 1997;29(1):129-139.
231. Liu Y, Tsuchida A, Cohen MV, Downey JM. Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. *J Mol Cell Cardiol* 1995;27(3):883-892.
232. Marra F, Bertolani C. Adipokines in liver diseases. *Hepatology* 2009 ;50(3):957-969.
233. Blaner WS. Retinol-binding protein: the serum transport protein for vitamin A. *Endocr Rev* 1989;10(3):308-316.
234. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. *N Engl J Med* 2006;354(24):2552-2563.
235. Wagnerberger S, Schäfer C, Bode C, Parlesak A. Saturation of retinol-binding protein correlates closely to the severity of alcohol-induced liver disease. *Alcohol* 2006;38(1):37-43.
236. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. *Nature* 2005;436(7049):356-362.

237. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. *Diabetes Care* 2006;29(11):2457-2461.
238. Lee DC, Lee JW, Im JA. Association of serum retinol binding protein 4 and insulin resistance in apparently healthy adolescents. *Metabolism* 2007;56(3):327-331.
239. Yao-Borengasser A, Varma V, Bodles AM, Rasouli N, Phanavanh B, Lee MJ, Starks T, Kern LM, Spencer HJ 3rd, Rashidi AA, McGehee RE Jr, Fried SK, Kern PA. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. *J Clin Endocrinol Metab* 2007;92(7):2590-2597.
240. Seo JA, Kim NH, Park SY, Kim HY, Ryu OH, Lee KW, Lee J, Kim DL, Choi KM, Baik SH, Choi DS, Kim SG. Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease. *Clin Endocrinol (Oxf)* 2008;68(4):555-560.
241. Wu H, Jia W, Bao Y, Lu J, Zhu J, Wang R, Chen Y, Xiang K. Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2008;79(2):185-190.
242. Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. *J Clin Endocrinol Metab* 2007;92(5):1971-1974.
243. Wu H, Jia W, Bao Y, Lu J, Zhu J, Wang R, Chen Y, Xiang K. Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2008;79(2):185-190.
244. Ost A, Danielsson A, Lidén M, Eriksson U, Nystrom FH, Strålfors P. Retinol-binding protein-4 attenuates insulin-induced phosphorylation of IRS1 and ERK1/2 in primary human adipocytes. *FASEB J* 2007;21(13):3696-3704.
245. Okaya T, Lentsch AB. Peroxisome proliferator-activated receptor-alpha regulates postischemic liver injury. *Am J Physiol Gastrointest Liver Physiol* 2004;286(4):G606-G612.
246. Yki-Järvinen H. Thiazolidinediones. *N Engl J Med*. 2004 Sep 9;351(11):1106-18.
247. Xu SQ, Li YH, Hu SH, Chen K, Dong LY. Effects of Wy14643 on hepatic ischemia reperfusion injury in rats. *World J Gastroenterol* 2008;14(45):6936-6942.
248. Kuboki S, Shin T, Huber N, Eismann T, Galloway E, Schuster R, Blanchard J, Zingarelli B, Lentsch AB. Peroxisome proliferator-activated receptor-gamma protects against hepatic ischemia/reperfusion injury in mice. *Hepatology* 2008;47(1):215-224.
249. Akahori T, Sho M, Hamada K, Suzaki Y, Kuzumoto Y, Nomi T, Nakamura S, Enomoto
250. K, Kanehiro H, Nakajima Y. Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice. *J Hepatol* 2007;47(6):784-792.
251. Shin T, Kuboki S, Huber N, Eismann T, Galloway E, Schuster R, Blanchard J, Pritts TA, Lentsch AB. Activation of peroxisome proliferator-activated receptor-gamma during hepatic ischemia is age-dependent. *J Surg Res* 2008;147(2):200-205.
252. Teixeira AR, Molan NT, Bellodi-Privato M, Coelho AM, Leite KR, Seguro AC, Bacchella T, Machado MC. Rosiglitazone-enriched diet did not protect liver ischemia-reperfusion injury in a rat model. *Acta Cir Bras* 2008;23(4):378-383.
253. Teranishi T, Ohara T, Maeda K, Zenibayashi M, Kouyama K, Hirota Y, Kawamitsu H, Fujii M, Sugimura K, Kasuga M. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. *Metabolism* 2007;56(10):1418-1424.
254. Lin KD, Chang YH, Wang CL, Yang YH, Hsiao PJ, Li TH, Shin SJ. Thiazolidinedione addition reduces the serum retinol-binding protein 4 in type 2 diabetic patients treated with metformin and sulfonylurea. *Transl Res* 2008;151(6):309-314.



255. Yang B, Brown KK, Chen L, Carrick KM, Clifton LG, McNulty JA, Winegar DA, Strum JC, Stimpson SA, Pahel GL. Serum adiponectin as a biomarker for in vivo PPAR $\gamma$  activation and PPAR $\gamma$  agonist-induced efficacy on insulin sensitization/lipid lowering in rats. *BMC Pharmacol* 2004;4:23.
256. Martens FM, Rabelink TJ, op 't Roodt J, de Koning EJ, Visseren FL. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. *Eur Heart J* 2006;27(13):1605-1609.
257. Aleixandre de Artiñano A, Miguel Castro M. Experimental rat models to study the metabolic syndrome. *Br J Nutr* 2009;102(9):1246-1253.
258. Bray GA. The Zucker-fatty rat: a review. *Fed Proc* 1977;36(2):148-153.
259. Kamada N, Calne RY. Orthotopic liver transplantation in the rat. Technique using cuff for portal vein anastomosis and biliary drainage. *Transplantation* 1979;28(1):47-50.
260. Amersi F, Buelow R, Kato H, Ke B, Coito AJ, Shen XD, Zhao D, Zaky J, Melinek J, Lassman CR, Kolls JK, Alam J, Ritter T, Volk HD, Farmer DG, Ghobrial RM, Busuttill RW, Kupiec-Weglinski JW. Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury. *J Clin Invest* 1999;104(11):1631-1639.
261. Sun Z, Klein AS, Radaeva S, Hong F, El-Assal O, Pan HN, Jaruga B, Batkai S, Hoshino S, Tian Z, Kunos G, Diehl AM, Gao B. In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. *Gastroenterology* 2003;125(1):202-215.
262. Camargo CA Jr, Madden JF, Gao W, Selvan RS, Clavien PA. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. *Hepatology* 1997;26(6):1513-1520.
263. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. *Hypertension* 1998;31(1 Pt 2):349-355.
264. Bayorh MA, Eatman D, Walton M, Socci RR, Thierry-Palmer M, Emmett N. A-779 attenuates angiotensin-(1-7) depressor response in salt-induced hypertensive rats. *Peptides* 2002;23(1):57-64.
265. Cottart CH, Do L, Blanc MC, Vaubourdolle M, Descamps G, Durand D, Galen FX, Clot JP. Hepatoprotective effect of endogenous nitric oxide during ischemia-reperfusion in the rat. *Hepatology* 1999;29(3):809-813.
266. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. *J Cell Biol* 1992;119(3):493-501.
267. Brown KM, Brems JJ, Moazzam FN, Hartman GG, Gamelli RL, Ding JW. The nitric oxide donor molsidomine improves survival and reduces hepatocyte apoptosis in cholestasis and endotoxemia. *J Am Coll Surg* 2003;197(2):261-269.
268. Ye VZ, Duggan KA. Modulation of the intrahepatic renin-angiotensin system after stimulation of the gastric sodium monitor in the rat. *Clin Sci (Lond)* 2000;98(1):57-64.
269. Naik GO, Moe GW, Armstrong PW. Specific and non-specific measurements of tissue angiotensin II cascade members. *J Pharm Biomed Anal* 2001;24(5-6):947-955.
270. Joyner J, Neves LA, Granger JP, Alexander BT, Merrill DC, Chappell MC, Ferrario CM, Davis WP, Brosnihan KB. Temporal-spatial expression of ANG-(1-7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats. *Am J Physiol Regul Integr Comp Physiol* 2007;293(1):R169-R177.
271. Ferrario CM, Averill DB, Brosnihan KB, Chappell MC, Iskandar SS, Dean RH, Diz DI. Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat. *Kidney Int* 2002;62(4):1349-1357.
272. Senanayake PD, Moriguchi A, Kumagai H, Ganten D, Ferrario CM, Brosnihan KB. Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats. *Peptides* 1994;15(5):919-926.
273. Nakamoto H, Ferrario CM, Fuller SB, Robaczewski DL, Winicov E, Dean RH. Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension. *Hypertension* 1995;25(4 Pt 2):796-802.

274. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001;25(4):402-408.
275. Pan CH, Lin JL, Lai LP, Chen CL, Stephen Huang SK, Lin CS. Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial fibrillation. *FEBS Lett* 2007;581(3):526-534.
276. Kim MS, Sweeney TR, Shigenaga JK, Chui LG, Moser A, Grunfeld C, Feingold KR. Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells. *Metabolism* 2007;56(2):267-279.
277. Bhattacharya N, Dufour JM, Vo MN, Okita J, Okita R, Kim KH. Differential effects of phthalates on the testis and the liver. *Biol Reprod* 2005;72(3):745-754.
278. Wada K, Fujimoto K, Fujikawa Y, Shibayama Y, Mitsui H, Nakata K. Sinusoidal stenosis as the cause of portal hypertension in choline deficient diet induced fatty cirrhosis of the rat liver. *Acta Pathol Jpn.* 1974 Mar;24(2):207-17.
279. Arvidsson D, Svensson H, Haglund U. Laser-Doppler flowmetry for estimating liver blood flow. *Am J Physiol* 1988;254(4 Pt 1):G471-G476.
280. Almond NE, Wheatley AM. Measurement of hepatic perfusion in rats by laser Doppler flowmetry. *Am J Physiol* 1992;262(2 Pt 1):G203-G209.
281. Vollmar B, Glasz J, Menger MD, Messmer K. Leukocytes contribute to hepatic ischemia/reperfusion injury via intercellular adhesion molecule-1-mediated venular adherence. *Surgery* 1995;117(2):195-200.
282. Aiba M, Takeyoshi I, Ohwada S, Kawashima Y, Iwanami K, Sunose Y, Yamada T, Tsutsumi H, Matsumoto K, Morishita Y. Novel nitric oxide donor (FK409) ameliorates liver damage during extended liver resection with warm ischemia in dogs. *J Am Coll Surg* 2001;193(3):264-271.
283. Hortelano S, Genaro A, Boscá L. Phorbol esters induce nitric oxide synthase activity in rat hepatocytes. Antagonism with the induction elicited by lipopolysaccharide. *J Biol Chem* 1992;267(35):24937-24940.
284. Mayoral P, Criado M, Hidalgo F, Flores O, Arévalo MA, Eleno N, Sanchez-Rodriguez A, Lopez-Novoa JM, Esteller A. Effects of chronic nitric oxide activation or inhibition on early hepatic fibrosis in rats with bile duct ligation. *Clin Sci* 1999;96(3):297-305.
285. Vázquez-Gil MJ, Mesonero MJ, Flores O, Criado M, Hidalgo F, Arévalo MA, Sanchez-Rodriguez A, Tunon MJ, Lopez-Novoa JM, Esteller A. Sequential changes in redox status and nitric oxide synthases expression in the liver after bile duct ligation. *Life Sci* 2004;75(6):717-732.
286. Uchinami H, Yamamoto Y, Kume M, Yonezawa K, Ishikawa Y, Taura K, Nakajima A, Hata K, Yamaoka Y. Effect of heat shock preconditioning on NF-kappaB/I-kappaB pathway during I/R injury of the rat liver. *Am J Physiol Gastrointest Liver Physiol* 2002;282(6):G962-G971.
287. Baykal A, Kaynaroglu V, Demirpençe E, Kiliç K, Sayek I, Sanaç Y. Experimental study of the effect of adrenaline tolerance on intestinal ischaemia-reperfusion. *Br J Surg* 1998;85(7):947-950.
288. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal Biochem* 1979;95(2):351-358.
289. Virág L, Szabó E, Bakondi E, Bai P, Gergely P, Hunyadi J, Szabó C. Nitric oxide-peroxynitrite-poly(ADP-ribose) polymerase pathway in the skin. *Exp Dermatol* 2002;11(3):189-202.
290. Minato K, Miyake Y, Fukumoto S, Yamamoto K, Kato Y, Shimomura Y, Osawa T. Lemon flavonoid, eriocitrin, suppresses exercise-induced oxidative damage in rat liver. *Life Sci* 2003;72(14):1609-1616.
291. Greenacre SA, Evans P, Halliwell B, Brain SD. Formation and loss of nitrated proteins in peroxynitrite-treated rat skin in vivo. *Biochem Biophys Res Commun* 1999;262(3):781-786.
292. Viera L, Ye YZ, Estévez AG, Beckman JS. Immunohistochemical methods to detect nitrotyrosine. *Methods Enzymol* 1999;301:373-381.

293. Zingarelli B, Szabó C, Salzman AL. Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase. *Gut* 1999;45(2):199-209.
294. Thai H, Wollmuth J, Goldman S, Gaballa M. Angiotensin subtype 1 Receptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitric-oxide synthase via activation of the AT2 receptor. *J Pharmacol Exp Ther* 2003;307(3):1171-1178.
295. Widder J, Behr T, Fraccarollo D, Hu K, Galuppo P, Tas P, Angermann CE, Ertl G, Bauersachs J. Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent. *Cardiovasc Res* 2004;63(1):161-167.
296. Li X, Meng Y, Wu P, Zhang Z, Yang X. Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat. *Regul Pept* 2007;138(1):15-25.
297. van der Vliet A, Eiserich JP, Cross CE. Nitric oxide: a pro-inflammatory mediator in lung disease? *Respir Res* 2000;1(2):67-72.
298. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. *Am J Physiol* 1996;271(5 Pt 1):C1424-C1437.
299. Grisham MB, Jour'dHeuil D, Wink DA. Nitric oxide. I. Physiological chemistry of nitric oxide and its metabolites: implications in inflammation. *Am J Physiol* 1999;276(2 Pt 1):G315-G321.
300. Stamler JS. Redox signaling: nitrosylation and related target interactions of nitric oxide. *Cell* 1994;78(6):931-936.
301. Sivarajah A, McDonald MC, Thiernermann C. The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-gamma antagonist. *J Pharmacol Exp Ther* 2005;313(2):896-901.
302. Yue TI TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, Ohlstein EH. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. *Circulation* 2001;104(21):2588-2594.
303. Gjøen T, Bjerkelund T, Blomhoff HK, Norum KR, Berg T, Blomhoff R. Liver takes up retinol-binding protein from plasma. *J Biol Chem* 1987;262(23):10926-10930.
304. Tsutsumi C, Okuno M, Tannous L, Piantedosi R, Allan M, Goodman DS, Blaner WS. Retinoids and retinoid-binding protein expression in rat adipocytes. *J Biol Chem* 1992;267(3):1805-1810.
305. Ramalho FS, Ramalho LN, Castro-e-Silva Júnior O, Zucoloto S, Corrêa FM. Effect of angiotensin-converting enzyme inhibitors on liver regeneration in rats. *Hepatogastroenterology* 2002;49(47):1347-1351.
306. Yayama K, Sugiyama K, Miyagi R, Okamoto H. Angiotensin-converting enzyme inhibitor enhances liver regeneration following partial hepatectomy: involvement of bradykinin B2 and angiotensin AT1 receptors. *Biol Pharm Bull* 2007;30(3):591-594.
307. Spät A, Enyedi P, Hajnóczky G, Hunyady L. Generation and role of calcium signal in adrenal glomerulosa cells. *Exp Physiol* 1991;76(6):859-885.
308. Ohyama K, Yamano Y, Chaki S, Kondo T, Inagami T. Domains for G-protein coupling in angiotensin II receptor type I: studies by site-directed mutagenesis. *Biochem Biophys Res Commun* 1992;189(2):677-683.
309. So T, Nakashima Y, Imamura M, Arakawa K. Effects of local inhibition of the cardiac renin-angiotensin system with CV-11974 in a canine ischaemia-reperfusion model. *Clin Exp Pharmacol Physiol* 1998;25(7-8):503-509.
310. Masuko H, Jin MB, Horiuchi H, Suzuki T, Taniguchi M, Shimamura T, Fukai M, Magata S, Ogata K, Ishikawa H, Fujita M, Nagashima K, Furukawa H, Todo S. Protective effect of angiotensin II type I receptor antagonist, CV-11974, on ischemia and reperfusion injury of the liver. *Transplantation* 2001;71(8):1034-1039.
311. Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM. Serine/threonine protein kinases and apoptosis. *Exp Cell Res* 2000;256(1):34-41.

312. Liang TB, Man K, Kin-Wah Lee T, Hong-Teng Tsui S, Lo CM, Xu X, Zheng SS, Fan ST, Wong J. Distinct intragraft response pattern in relation to graft size in liver transplantation. *Transplantation* 2003;75(5):673-678.
313. Natori S, Selzner M, Valentino KL, Fritz LC, Srinivasan A, Clavien PA, Gores GJ. Apoptosis of sinusoidal endothelial cells occurs during liver preservation injury by a caspase-dependent mechanism. *Transplantation* 1999;68(1):89-96.
314. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. *Hypertension* 2006;47(3):515-521.
315. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. *J Biol Chem* 2002;277(17):14838-14843.
316. Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, Boomsma F, van Gilst WH. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. *Circulation* 2002;105(13):1548-1550.
317. Benter IF, Yousif MH, Cojocel C, Al-Maghrebi M, Diz DI. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. *Am J Physiol Heart Circ Physiol* 2007;292(1):H666-H672.
318. Ferdinandy P, Schulz R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. *Br J Pharmacol* 2003;138(4):532-543.
319. MacMillan-Crow LA, Crow JP, Thompson JA. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. *Biochemistry* 1998;37(6):1613-1622.
320. Smith FR, Goodman DS. The effects of diseases of the liver, thyroid, and kidneys on the transport of vitamin A in human plasma. *J Clin Invest* 1971;50(11):2426-2436.
321. Smith JC Jr, Brown ED, White SC, Finkelstein JD. Letter: Plasma vitamin A and zinc concentration in patients with alcoholic cirrhosis. *Lancet* 1975;1(7918):1251-1252.
322. McClain CJ, Van Thiel DH, Parker S, Badzin LK, Gilbert H. Alterations in zinc, vitamin A, and retinol-binding protein in chronic alcoholics: a possible mechanism for night blindness and hypogonadism. *Alcohol Clin Exp Res* 1979;3(2):135-141.
323. Rosales FJ, Ritter SJ, Zolfaghari R, Smith JE, Ross AC. Effects of acute inflammation on plasma retinol, retinol-binding protein, and its mRNA in the liver and kidneys of vitamin A-sufficient rats. *J Lipid Res* 1996;37(5):962-971.
324. Rosales FJ, Ross AC. Acute inflammation induces hyporetinemia and modifies the plasma and tissue response to vitamin A supplementation in marginally vitamin A-deficient rats. *J Nutr* 1998;128(6):960-966.
325. Gieng SH, Raila J, Rosales FJ. Accumulation of retinol in the liver after prolonged hyporetinolemia in the vitamin A-sufficient rat. *J Lipid Res* 2005;46(4):641-649.
326. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. *Cell Metab* 2005;1(1):15-25.
327. Kola B, Boscaro M, Rutter GA, Grossman AB, Korbonits M. Expanding role of AMPK in endocrinology. *Trends Endocrinol Metab* 2006;17(5):205-215.
328. Lage R, Diéguez C, Vidal-Puig A, López M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. *Trends Mol Med* 2008;14(12):539-549.
329. Janke J, Engeli S, Boschmann M, Adams F, Böhnke J, Luft FC, Sharma AM, Jordan J. Retinol-binding protein 4 in human obesity. *Diabetes* 2006;55(10):2805-2810.
330. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Schleicher E, Fritsche A, Häring HU. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. *Diabetes Care* 2007;30(5):1173-1178.

331. Wu H, Wei L, Bao Y, Lu J, Huang P, Liu Y, Jia W, Xiang K. Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue. *Am J Physiol Endocrinol Metab* 2009;296(4):E628-E634.
332. Lanne B, Dahllöf B, Lindahl C, Ebefors K, Kanmert I, von Bahr H, Miliotis T, Nyström AC, Arnerup G, Paulsons I, Kerb S, Oakes N. PPARalpha and PPARgamma regulation of liver and adipose proteins in obese and dyslipidemic rodents. *J Proteome Res* 2006;5(8):1850-1859.
333. Mody N, Graham TE, Tsuji Y, Yang Q, Kahn BB. Decreased clearance of serum retinol-binding protein and elevated levels of transthyretin in insulin-resistant ob/ob mice. *Am J Physiol Endocrinol Metab* 2008;294(4):E785-E793.
334. Zhao CY, Jiang LL, Li L, Deng ZJ, Liang BL, Li JM. Peroxisome proliferator activated receptor-gamma in pathogenesis of experimental fatty liver disease. *World J Gastroenterol* 2004;10(9):1329-1332.
335. Inoue M, Ohtake T, Motomura W, Takahashi N, Hosoki Y, Miyoshi S, Suzuki Y, Saito H, Kohgo Y, Okumura T. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. *Biochem Biophys Res Commun* 2005;336(1):215-222.